The commercial license will become effective upon completion of the transition of commercial rights from Biogen back to ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Biosimilars and Biologics Market Driven by aging populations and patent cliffs, the biosimilars & biologics market will grow from ~$531B in ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

Harrow has entered into an agreement with Samsung Bioepis for the U.S. commercial rights to two ophthalmology biosimilars, ...

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).